Document:

<PAGE>   1
                                                                   EXHIBIT 10.49

                                BIO-PLEXUS, INC.

                      NON-STATUTORY STOCK OPTION AGREEMENT

         THIS AGREEMENT dated as of October 30, 2000 between Bio-Plexus, Inc., a
Connecticut corporation (the "Company") and Carl Sahi (the "Participant").

         WHEREAS, the Company is entering into this Agreement and delivering
this Agreement to the Participant as contemplated by that certain Letter
Agreement dated October 30, 2000 between the Participant and the Company, (the
"Letter Agreement").

         NOW, THEREFORE, in consideration of the premises, the mutual covenants
hereinafter set forth, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and the
Participant agree as follows:

         1. Grant of Option. The Company hereby grants to the Participant, a
non-statutory stock option (the "Option"), pursuant to the Company's 1991
Long-term Incentive Plan, or any successor plan thereto (the "Plan"), to
purchase up to an aggregate of 25,000 shares (the "Shares") of Common Stock, no
par value ("Common Stock"), of the Company at a price of U.S. $2.00 per Share
(the "Exercise Price"), purchasable as set forth in and subject to the terms and
conditions of this Agreement and the Plan.

         2. Exercise of Option and Provisions for Termination.

         (a) Terms and Exercise of Option. Subject to subsections (b) through
(e) below, the Option shall become fully exercisable with respect to the Shares
upon the execution of this Agreement.

         (b) Expiration Date. Except as otherwise provided in this Agreement,
the Option may not be exercised after the date (hereinafter the "Expiration
Date") that is the tenth anniversary of the Date of Grant.

         (c) Exercise Procedure. Subject to the conditions set forth in this
Agreement, the Option shall be exercised by the Participant's delivery of
written notice of exercise to the chief financial officer of the Company,
specifying the number of Shares to be purchased and the aggregate Exercise Price
to be paid therefor and accompanied by payment in full in accordance with
Section 3. Such exercise shall be effective upon receipt by the chief financial
officer of the Company of such written notice together with the required
payment. The Participant may purchase less than the total number of Shares
covered hereby, provided that no partial exercise of the Option may be for any
fractional Share or for less than ten whole Shares.

         (d) Exercise Period Upon Death or Disability. If the Participant dies
or becomes disabled (within the meaning of Section 22(e) (3) of the Code) prior
to the Expiration Date, during the term of the Letter Agreement or if the
Participant dies within three months after the termination of the Letter
Agreement, the Option shall be exercisable with respect to all Options then
presently exercisable, within the period of one year following the date of
death or disability of the Participant (but in no event after the Expiration
Date), by the Participant, the Participant's legal representative (in the event
of legal incapacity) or by the person to whom the Option is

                                       1
<PAGE>   2
transferred by will or the laws of descent and distribution. Except as otherwise
indicated by the context, the term "Participant", as used in this Agreement,
shall be deemed to include the estate of the Participant, or any person who
acquires the right to exercise the Option by bequest or inheritance or otherwise
by reason of the death of the Participant.

         (e) Termination of Option. If the Participant breaches any of his
obligations set forth in the Letter Agreement, the right to exercise the Option
shall immediately terminate and, thereafter, the Option shall be of no further
force or effect as to the Company or the Participant upon such termination.

         3. Payment of Exercise Price. Payment of the aggregate Exercise Price
for Shares purchased upon exercise of the Option shall be made by delivery to
the chief financial officer of the Company of (a) cash or by a certified or
cashier's check payable to the order of the Company, (b) shares of Common Stock
(valued at the Fair Market Value, as such term is defined in the Plan, on the
date of purchase), or (c) a combination of the methods of payment set forth in
clauses (a) and (b) hereof.

         4. Delivery of Shares. The Company shall, upon payment of the aggregate
Exercise Price for the number of Shares purchased and paid for, make prompt
delivery of such Shares to the Participant, provided that if any law or
regulation requires the Company to take any action with respect to such Shares
before the issuance thereof, then the date of delivery of such Shares shall be
extended for the period necessary to complete such action. No Shares shall be
issued and delivered upon exercise of the Option unless and until, in the
opinion of counsel for the Company, any applicable registration requirements of
the Securities Act of 1933, as amended (the "Securities Act"), any applicable
listing requirements of any national securities exchange on which stock of the
same class is then listed, and any other requirements of law or of any
regulatory bodies having jurisdiction over such issuance and delivery, shall
have been fully complied with.

         5. Non-transferability of Option. Except as provided in subsection (d)
of Section 2, or as otherwise agreed to by the Board of Directors or a committee
thereof, the Option is personal and no rights granted hereunder may be
transferred, assigned, pledged or hypothecated in any way (whether by operation
of law or otherwise) nor shall any such rights be subject to execution,
attachment or similar process. Upon any attempt to transfer, assign, pledge,
hypothecate or otherwise dispose of the Option or of such rights contrary to the
provisions hereof, or upon the levy of any attachment or similar process upon
the Option or such rights, the Option and such rights shall, at the election of
the Company, become null and void.

         6. No Special Employment Rights. Nothing contained in the Plan or this
Agreement shall be construed or deemed by any person under any circumstances to
create a relationship of employer and employee between the Company and the
Participant. The Participant and the Company acknowledge and agree that as of
the date hereof, the Letter Agreement and this Agreement are the only agreements
governing the relationship between the Company and the Participant.

         7. Rights as a Shareholder. The Participant shall have no rights as a
Shareholder with respect to any Shares which may be purchased by exercise of the
Option unless and until a

                                       2
<PAGE>   3
certificate representing such Shares is duly issued and delivered to the
Participant. No adjustment shall be made for dividends or other rights for which
the record date is prior to the date such stock certificate is issued except as
provided for in Section 8 of this Agreement.

         8. Recapitalization. In the event that the outstanding shares of Common
Stock of the Company are changed into or exchanged for a different number or
kind of shares or other securities of the Company by reason of any
recapitalization, reclassification, stock split, stock dividend, combination or
subdivision, the Board of Directors or a committee thereof, in its discretion,
may make appropriate adjustments in the number and kind of Shares to which the
Option shall be exercisable. Such adjustment to the Option may be made without
change in the total price applicable to the unexercised portion of the Option,
and a corresponding adjustment in the Exercise Price per Share may be made. No
such adjustment shall be made which would, within the meaning of any applicable
provisions of the Code, constitute a modification, extension or renewal of the
Option or a grant of additional benefits to the Participant.

         9. Withholding Taxes. The Company's obligation to deliver Shares upon
the exercise of the Option shall be subject to the Participant's satisfaction of
all applicable federal, state and local income and employment tax withholding
requirements.

         10. Severability. In the event that any provision or portion of this
Agreement shall be determined to be invalid or unenforceable for any reason, in
whole or in part, in any jurisdiction, the remaining provisions of this
Agreement shall be unaffected thereby and shall remain in full force and effect
to the fullest extent permitted by law in such jurisdiction, and such invalidity
or unenforceability shall have no effect in any other jurisdiction.

         11. The Plan. The Plan, a summary of which has been distributed with
this Agreement is incorporated herein by reference and is made a part of this
Agreement as if fully set forth herein. This Agreement is subject to, and the
Company and the Participant agree to be bound by, all of the terms and
conditions of the Plan. The Plan shall control in the event there is any express
conflict between the Plan and the terms hereof, and on such matters that are not
expressly covered in this Agreement. Subsequent amendments to the Plan shall
not, without the consent of the Participant, adversely affect the Participant's
rights under this Agreement. Capitalized terms used herein which are not
otherwise defined herein shall have the meaning ascribed thereto in the Plan.

         12. Acknowledgement and Legend.

         (a) The Participant acknowledges and agrees that (i) because of his
position on the Board of Directors of the Company, the Participant may be deemed
to be an "affiliate" thereof (as such term is defined in Rule 144 promulgated
under the Securities Act); (ii) the resale by an affiliate of the Company of the
Shares acquired upon any exercise of the Option is restricted by law,
notwithstanding any registration of the Shares on Form S-8 (or similar successor
form) promulgated under the Securities Act; (iii) any resale of the Shares by an
affiliate of the Company pursuant to said Rule 144 would be subject to the
volume limitations contained in paragraph (e) thereof; and (iv) the Participant
will not sell such Shares in violation of Rule 144(e) or any other rule or
regulation under the Securities Act.

                                       3
<PAGE>   4
         (b) Legend on Stock Certificates. So long as the Participant remains an
affiliate of the Company, all stock certificates representing Shares issued to
the Participant upon exercise of the Option shall have affixed thereto a legend
substantially in the following form, in addition to any other legends required
by applicable state law:

                  "The Shares of stock represented by this certificate are
                  subject to the volume limitations of Rule 144(e) promulgated
                  under the Securities Act of 1933, as amended."

                  By making payment upon exercise of the Option, the Participant
shall be deemed to have reaffirmed, as of the date of such payment, the
representations made in this Section 12.

         13. Miscellaneous; Notices.

         (a) This Agreement and any instrument delivered pursuant to this
Agreement shall be governed by and interpreted in accordance with the laws of
the State of Connecticut, without regard to the conflicts of law rules thereof.

         (b) Any controversy or claim arising out of or relating to this
Agreement, or any breach thereof, shall be resolved through final and binding
arbitration in accordance with the Employment Dispute Resolution Rules of the
American Arbitration Association then in effect. Judgment upon any arbitration
award rendered may be entered in any court having jurisdiction thereof. The
arbitration shall be held in the area where the Company then has its principal
place of business. The arbitration award may include an award of attorneys' fees
and costs.

         (c) This Agreement shall extend to, be binding upon and inure to the
benefit of Participant and his legal representatives, heirs, successors and
assigns (subject, however, to the limitations set forth in Section 5 with
respect to transfer of this Agreement or any rights hereunder), and upon the
Company and its successors and assigns, regardless of any change in the business
structure of the Company, be it through spinoff, merger, sale of stock, sale of
assets or any other transaction.

         (d) This Agreement and the Plan contain the entire agreement of the
parties with respect to the subject matter hereof. With the consent of the
Participant, the Board of Directors or a committee thereof, may amend this
Agreement in a manner not inconsistent with the Plan.

         (e) The waiver of any breach of any duty, term or condition of this
Agreement shall not be deemed to constitute a waiver of any preceding or
succeeding breach of the same or of any other duty, term or condition of this
Agreement.

         (f) All notices pursuant to this Agreement will be in writing and will
be sent by personal delivery, telecopier, electronic mail or by prepaid
registered or certified mail, return receipt requested, addressed to the parties
hereto at the addresses set forth beneath their names on the signature page
hereto or to such other addresses as may hereafter be specified by like notice
in writing by either of the parties, and will be deemed given (i) upon receipt
if by personal delivery, (ii) on the day on which delivered if delivered by
telecopier (with confirmation of receipt (such receipt to be established by
acceptable protocol)), (iii) upon mailing if sent by registered or certified
mail or (iv) when transmitted if delivered by electronic mail (with

                                       4
<PAGE>   5
satisfactory evidence of transmittal (such evidence of transmittal to be
established by acceptable protocol)). Copies of all notices shall be sent to:
Paul, Hastings, Janofsky & Walker LLP, 1055 Washington Boulevard, Stamford,
Connecticut 06901, Attention: Esteban A. Ferrer, Esq., Telecopier No.
203-359-3031, E-mail Address: eaferrer@phjw.com.

         (g) The headings of the sections of this Agreement are inserted for
convenience of reference only and will not be deemed to constitute a part hereof
or to affect the meaning hereof.

         (h) This Agreement may be executed in counterparts, each of which will
be deemed an original but all of which will together constitute one and the same
agreement.

Date of Grant:                             BIO-PLEXUS, INC.

October 30, 2000                           By:
                                              ---------------------------------
                                              Name: John S. Metz
                                             Title: President & CEO
                                           Address: 129 Reservoir Road
                                                    Vernon, CT  06066

                            PARTICIPANT'S ACCEPTANCE

         The undersigned hereby accepts the foregoing Agreement and agrees to
the terms and conditions thereof. The undersigned hereby acknowledges receipt of
a copy of the Company's summary of the Plan.

                                           PARTICIPANT

                                           ------------------------------------
                                              Name: Carl Sahi
                                             Title: Director
                                           Address: 389 High Street
                                                    Coventry, CT 06238

                                       5<PAGE>   1
                                                                   EXHIBIT 10.50

December 6, 2000

Mr. Christopher C. Zorn
32 Planting Field Road
Medfield, MA  02052

Dear Chris:

I am pleased to offer you the position of executive vice president of sales for
Bio-Plexus, Inc. Your employment will begin on a mutually agreed upon date. In
this role, you will report directly to me and will be based at our corporate
office in Vernon, Connecticut. The basic terms and conditions of your employment
are summarized below:

Position              Executive Vice President of Sales for Bio-Plexus, Inc

Base Salary           $135,000 annually, payable in accordance with the
                      company's standard payroll practices. You will be eligible
                      for an annual performance review and a standard merit
                      increase if recommended and approved by the Compensation
                      Committee.

Retention Bonuses     Retention and stay bonuses will be paid as follows:

                           -    A retention bonus of $16,000 for year 2001 paid
                                on a monthly basis. This $16,000 bonus will
                                continue through December 31, 2002, assuming
                                your performance is at expected levels.

                           -    A $10,000 stay bonus to be paid on July 1, 2001.

                      Retention and stay bonuses pay will be deducted from any
                      performance bonus payout below.

Performance Bonus     Up to 100% of base salary for achievement of individual
                      and corporate goals. Your individual performance goals and
                      objectives will be in place no later than January 15,
                      2001. A bonus schedule as follows and based on net product
                      sales to budget as established by the Board for Directors:

<TABLE>
<S>                                     <C>
                            88-90%      $20,000
                            91-93%      $25,000
                            94-96%      $30,000
</TABLE>
<PAGE>   2
Mr. Christopher C. Zorn
December 6, 2000
Page 2

<TABLE>
<S>                                     <C>
                            97-99%      $40,000
                            100%        $67,500
                            101-103%    $72,500
                            104-107%    $80,000
                            108-110%    $90,000
                            111-115%    $105,000
                            116-119%    $120,000
                            120+%       $135,000
</TABLE>

                      -    If budgeted profit goals are achieved, you are
                           eligible for full payment for performance to sales
                           objectives up to 110% of budgeted net product sales.
                           Under a circumstance whereby revenue of net product
                           sales goals are achieved but corporate profitability
                           to budget is not, you will be guaranteed a bonus
                           payout of 80% for achievement of sales targets. For
                           example if sales budget is achieved you would be
                           eligible for a bonus of $67,500; however, if budget
                           profitability goals are not achieved, you will
                           receive 80% or $54,000.

                      -    Payments for net sales above 110% of budget will be
                           paid according to the following:

                           -    Achievement of budgeted profit goals but less
                                than targeted profit goals above budget.

                                    o    Full payment or 100% of the increment
                                         up to 110% and 80% payment of the
                                         increment above 110%. Example: if sales
                                         are 116% of budget, payment would be
                                         $114,000 (i.e. $90,000 plus $24,000
                                         which is 80% of the increment above
                                         $90,000 payment level).

                           -    Achievement of targeted profit goals above
                                budget: full payout or 100% at all levels of
                                performance to budgeted net sales goals.

                      The performance bonus payment will be made - in a gross
                      amount less any applicable taxes and will become payable
                      following the close of the fiscal year on December 31 and
                      within a reasonable time period after determination by the
                      Company's Board of Directors as to relevant performance
                      attainment based on established goals.
<PAGE>   3
Mr. Christopher C. Zorn
December 6, 2000
Page 3

Stock Options         An option package of 150,000 shares with an exercise price
                      at the grant date will be made within 10 business days
                      from date of hire.. Of these 150,000 share, 100,000 shares
                      will be retention options which will vest over three
                      years. The remaining 50,000 shares will be performance
                      options which will vest under one of two occurrences:

                      1.   The end of seven years.

                      2.   When net product sales revenue for a cumulative,
                           sequential 12-month period totals $15 million.

                      In the event of a Change of Control, as defined in the
                      Bio-Plexus, Inc. Non-Statutory Stock Option Agreement to
                      be signed between you and the Company, and pursuant to
                      Section 9 of that Agreement, you will become fully vested
                      in all retention options.. Performance options will become
                      fully vested and exercisable at the discretion of the
                      Board of Directors. For clarity, "Change of Control" is
                      defined below.

Vacation              Three weeks annually

Employee Health       You will be able to participate in the company's medical
and Other Benefits    and dental programs and all  other benefit programs that
                      will be developed over time.

Severance             You will be entitled to receive six months of salary,
                      medical benefits continuation and bonus compensation that
                      was earned but not paid upon your termination by the
                      company for any reason other than for cause. If your
                      employment is terminated by the company for reasons other
                      than cause or performance your bonus for the current year
                      will vest on a pro rata basis and will be paid at the end
                      of the fiscal year as though you were currently employed.<
                      In addition, any retention stock options not completely
                      vested will immediately vest on a pro rata basis
                      (reference Attachment 1). Only the following shall
                      constitute "cause" for such termination: (i) material
                      failure to perform a substantial portion of your duties
                      and responsibilities hereunder, which failure continues
                      after written notice given to you by the President of the
                      Company; (ii) conduct by you that is dishonest, fraudulent
                      or unlawful relative to your employment by the Company;
                      (iii) conduct that constitutes gross negligence or willful
                      misconduct by you with respect to the Company; or (iv)
                      your conviction or admission of guilt of a felony and/or
                      crime
<PAGE>   4
Mr. Christopher C. Zorn
December 6, 2000
Page 4

                      involving moral turpitude, deceit, dishonesty or fraud.

Contingencies         This offer is contingent upon approval by the board
                      compensation committee for Bio-Plexus, your passing of a
                      drug test providing documentation that you have the right
                      to live and work in the United States, execution of other
                      standard employee documents and agreements, and after
                      successful completion of references to the satisfaction of
                      Bio-Plexus.

Indemnity             The Company agrees to indemnify you as provided under
                      Connecticut law and consistent with the terms of the
                      Certificate of Incorporation.

You should understand that all employees are employed at the will of the Company
for an indefinite period. Employees may resign from the Company at any time, for
any reason and may be terminated by the Company at any time, for any reason,
with or without notice.

Definition:

         "Change in Control" means any (i) consolidation or merger involving the
Company, if the shareholders of the Company immediately before such merger or
consolidation do not own, directly or indirectly, immediately following such
merger or consolidation, more than fifty percent (50%) of the combined voting
power of the outstanding voting securities of the corporation or other entity
resulting from such merger or consolidation in substantially the same proportion
as their ownership of the shares of Common Stock immediately before such merger
or consolidation; (ii) sale, lease, license, exchange or other transfer (in one
transaction or a series of related transactions) of all, or substantially all,
of the business and/or assets of the Company or assets representing over 50% of
the operating revenue of the Company; or any (iii) person (as such term is used
in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act")), other than Appaloosa Management, L.P. and its affiliates
and/or related funds, who is not, as of September 28, 2000, a controlling person
(as defined in Rule 405 under the Securities Act of 1933, as amended) (a
"Controlling Person") of the Company becomes (x) the beneficial owner (within
the meaning of Rule 13d-3 under the Exchange Act) of over 50% of the Company's
outstanding Common Stock or the combined voting power of the Company's then
outstanding voting securities entitled to vote generally or (y) a Controlling
Person of the Company.

Upon acceptance of this offer, please immediately return this signed letter in
the enclosed pre-addressed envelope. A copy will be provided to you upon
request. This offer of employment will be valid for one week from the date of
this letter.
<PAGE>   5
Mr. Christopher C. Zorn
December 6, 2000
Page 5

We look forward to you joining us at Bio-Plexus. We believe you will bring
significant contributions to the firm and also be a valuable member of the
executive management team.

Sincerely,

John Metz
Chief Executive Officer

I have read and accepted the above offer:

-----------------------------               ------------------------
Christopher C. Zorn                                  Date
<PAGE>   6
Mr. Christopher C. Zorn
December 6, 2000
Page 6

                                  ATTACHMENT 1

Pro rata Share Example:

<TABLE>
<S>               <C>               <C>
Options:          100m

Vesting           Year 1             33,333
                  Year 2             66,667
                  Year 3            100,000
</TABLE>

Termination without cause or for performance reasons after 17 months of complete
employment: pro rata shares that vest will be 17/36 = 47.2% of total,
approximately 47,200 shares, 33,333 of which have already vested. The additional
shares that vest and become exercisable are 13,867.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]